Novel therapies in myeloid neoplasms show limited benefit and increased costs over 15 years of follow-up in Southern Finland

Puntos clave

• Limited benefit was observed from novel therapies for myeloid neoplasms across a 15-year follow-up period.
• Costs associated with these treatments have increased significantly, raising concerns about healthcare resource allocation.
• This analysis included diverse patient data from Southern Finland, highlighting regional treatment trends and outcomes.
• The findings imply a need for re-evaluation of therapy approaches and healthcare spending in managing myeloid neoplasms.